Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RestorGenex has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, RestorGenex, 2017, NOV 13, 2017, View Source [SID1234521952]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Palatin Technologies has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Palatin Technologies, 2017, NOV 13, 2017, View Source [SID1234521951]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 13, 2017 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, reported the latest data updating the progression results at 19 weeks for all 20 patients, who have completed 6 vaccines in their Phase 1 clinical trial of ProscaVax for recurrent prostate cancer patients with increasing prostate specific antigen (PSA) (Press release, OncBioMune Pharmaceuticals, NOV 13, 2017, View Source [SID1234522143]). ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and have now completed the first follow-up at 19 weeks. 16 of 20 patients (80%) demonstrated stable disease/no prostate cancer progression. Only four patients progressed during ProscaVax therapy (3 PSA progression, 1 radiological progression in the brain).

The safety review confirmed there were no drug-related serious adverse events or dose-limiting toxicities resulting from the vaccine therapy.

OncBioMune is awaiting additional follow-up data related to our previously disclosed study data. This includes additional results on patients beyond the previously reported 12 of 15 patients that received ProscaVax vaccine, who exhibited an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay. Also, additional results on the 6 patients vaccinated after OncBioMune previously reported that 9 of 14 patients who received six ProscaVax vaccinations demonstrated increased PSA doubling times. Additional follow-up will provide longer follow-up intervals for the last six patients who completed the vaccine therapy.

"All the data to date is consistent with previous study data showing ProscaVax elicits immune responses to fight tumor growth in prostate cancer," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We are impressed that 80 percent of the patients treated with ProscaVax demonstrated stable disease. We look forward to continuing to follow the patients in this study to collect additional data and also to conducting a larger study to further validate the therapeutic benefit of our vaccine platform technology."

On November 13, 2017 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, reported that positive results from a Phase 1 clinical trial of TRC102 (methoxyamine) and Fludara (fludarabine) in patients with advanced hematologic malignancies were published in the journal Oncotarget (Volume 8, Number 45, pages 79864-79875) (Press release, Tracon Pharmaceuticals, NOV 13, 2017, View Source;p=RssLanding&cat=news&id=2316621 [SID1234522013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 trial enrolled a total of 20 patients, of whom 17 had measurable disease, with chronic lymphocytic leukemia (n=10), follicular lymphoma (n=3), diffuse large B cell lymphoma (n=3), plasma cell myeloma (n=2), mantle cell lymphoma (n=1), or anaplastic large cell lymphoma (n=1). Patients received one of five levels of TRC102 (15, 30, 60, 90, or 120 mg/m2) dosed intravenously on the initial day of recurring three week cycles in combination with Fludara dosed per label at 25 mg/m2 intravenously on days 1 through 5. Dose limiting toxicity was not observed. The most frequent toxicities were hematologic and were reversible when managed with supportive care. Four of the 17 patients (24%) experienced a partial response to treatment, and eight additional patients (8/17, 47%) had stable disease. The combination of TRC102 and Fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity.

"We have now observed TRC102 to be well-tolerated in combination with three separate chemotherapeutics, Alimta, Temodar and Fludara, and we are encouraged by the responses seen to date," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "We continue to make strong progress on the program and expect to report data from multiple National Cancer Institute-sponsored Phase 2 trials of TRC102 in 2018."

About TRC102

TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.